A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Study sponsor: Ascentage Pharma Group Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2028-05-25Estimated
Enrollment · participants486Estimated
Source updated2025-11-25Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.